Researchers found that caffeine blocks alcohol’s ability to increase dopamine in brain reward areas, potentially reducing ...

Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment ...

Oxford, UK-based Exscientia has been working with German biotech Evotec on the adenosine A2a receptor antagonist, which is being tested as a treatment for adult patients with advanced solid tumours.

Corvus Pharmaceuticals Inc. (CRVS) announced new data highlighting the potential of ciforadenant, the Company's adenosine A2A ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on ITOS stock, giving a Buy rating on November 12. Daina ...

a drug in the adenosine A2A receptor antagonist class. The Japanese drugmaker said (PDF) the decision wasn’t taken for clinical reasons, as trials suggested the drug had potential as a ...

This is likely due to caffeine blocking the receptors of a chemical found in human cells called adenosine. It may also be due ...

Dopamine’s effects in the brain are mediated by postsynaptic D1 and D2 receptors. Adenosine A1 and A2A receptors are uniquely positioned to counteract the excessive stimulation of dopamine receptors ...

The authors conclude that nonsynaptic release of ATP and subsequent activation of adenosine A 1 receptors contributes to suppression of thalamic activity and tremor, alone and during DBS ...

This inhibition results in an increase in local concentrations of adenosine which acts on the platelet A2-receptor thereby ... antagonize ACE inhibitors, β-blockers, diuretics, cholinesterase ...